Nabriva halts R&D, lays off 40% of staff in commercial-focused pivot for survival

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Nov 11, 2022 at 11:13: AM
via Irish biotech Nabriva Therapeutics has responded to the tough financial climate by putting all its chips on the approved bacterial skin medicine Sivextro, meaning its R&D projects and 40% of staff are now surplus to requirements.

article source
 

<



Similar threads

cafead
Nabriva hit with another FDA setback with complete response letter for antibiotic Contepo
Replies
0
Views
114
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Nabriva gets first approval in novel antibiotic class
Replies
0
Views
226
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Ahead of FDA decisions on one antibiotic, Nabriva plans resubmission of another
Replies
0
Views
246
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Nabriva&#039;s Antibiotic Contempo Turned Down by FDA Over Manufacturing Issues
Replies
0
Views
244
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Nabriva shares leap higher on antibiotic trial success
Replies
0
Views
593
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote